Roche Inks Another AAV Capsid Platform Technology Deal, With Avista Therapeutics

 
• By Alaric DeArment

Deal Snapshot: Roche and University of Pittsburgh spinout Avista Therapeutics signed the pact to enable the Swiss drug maker to develop gene therapies for retinal diseases using Avista’s platform tech.

Avista and Roche signed a deal to use Avista's capsid technology in developing gene therapies for eye diseases • Source: Shutterstock

More from Deals

More from Business